Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
1. SLRX regained compliance with Nasdaq Minimum Bid Price Requirement on September 4. 2. Company has until October 20 to meet Nasdaq Equity Standard Requirement. 3. A merger with Decoy Therapeutics is planned to enhance product offerings. 4. Decoy's pipeline targets respiratory infections and GI oncology needs. 5. Salarius' lead candidate is under evaluation for blood cancer treatment.